Post-Operative Myocardial Incident & Atrial Fibrillation
Trial statusRecruiting
Trial phaseNot listed
Trial typeObservational
Biological sexAll
Age18+
SponsorUniversity Hospital, Lille
About this trial
To explore predictors of major cardio-vascular events after cardiac surgery and trans-catheter valve implantation with a specific interest in studying mechanisms linking pre-operative leukocyte, fat and myocardial phenotypes with post-intervention outcomes.
Eligibility criteria
This trial does not accept healthy volunteersQualifiers
patients scheduled for cardiac surgery (coronary artery bypass graft surgery and/or valvular surgery) or transcatheter valve implantation
Disqualifiers
pregnant woman
urgent surgery or intervention
not able to consent to the protocol
Trial population
All adult patients schedulled for cardiac surgery (coronary artery bypass graft surgery and/or valvular surgery) or transcatheter valve implantation and referred to the University Hospital of Lille with inclusion criteria and no exclusion criteria.
Trial design
Design model
Cohort
Time perspective
Prospective
Treatments tested in this trial
Not listed
Trial groups
No trial groups listed
Trial outcomes
Primary outcomes
1
major cardio-vascular events after cardiac intervention (surgery or transcatheter valve implantation)
cardiovascular death, hospitalisation for heart failure, stroke, myocardial infarction, re-intervention
Time frame
from the day of intervention to 10 yearsSecondary outcomes
1
peri-operative myocardial injury
Area Under the Curve of blood troponin release during the 3 days following cardiac intervention
Time frame
3 days following intervention2
post-operative myocardial infarction (type 5 myocardial infarction)
myocardial infarction during the peri-operative time
Time frame
10 days following intervention3
post-operative atrial fibrillation
atrial fibrillation onset during post-op hospitalisation
Time frame
10 days following intervention4
major cardio-vascular events after cardiac intervention (surgery or transcatheter valve implantation)
cardiovascular death, hospitalisation for heart failure, stroke, myocardial infarction, re-intervention
Time frame
from the day of intervention to 1 yearSponsors and contacts
Click on the lead sponsor to view all of their trials.
Source ClinicalTrials.gov